The First Case of COVID-19 in South Kalimantan
Downloads
Background: In December 2019, a series of acute respiratory syndromes occurred in Wuhan, China. This syndrome became known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The sudden appearance and rapid global spread of SARS-CoV-2 led World Health Organization (WHO) to declare it as a pandemic disease on March 11, 2020. We will report the first case COVID-19 in South Kalimantan.
Case: A 44-year-old man was presented with fever, 7 days before admission. The patient also complained about cough with white phlegm and shortness of breath, accompanied by nausea with heartburn and decreased of appetite. He confessed that he just returned from local transmission areas of COVID-19. From physical examination, it was found SaO2 92% room air with bronchial sounds and ronchi in the lung. Chest X-ray showed peripheral infiltrates and diagnostic swab with RT-PCR in the oropharynx and nasopharynx showed that the patient was infected with SARS-CoV-2. HbsAg marker on this patient was also reactive. The patient then received supportive therapy as well as antiviral therapy. After 10 days of treatment, the patient was already free from the symptom, but swab evaluation remained positive. On the 31st day of treatment, the patient was finally declared cured with a negative swab result.
Conclusion: The number of COVID-19 cases has increased from time to time. Holistic treatment and rapid detection greatly affect the prognosis of this disease. Prevention through health protocols is also very important to reduce its spread.
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 Pathophysiology: A Review. Clin Immunol 2020; 215: 108427.
Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: Current State of the Science. Immunity 2020; 52: 910–941.
Merad M, Martin JC. Pathological Inflammation in Patients with COVID-19: A Key Role for Monocytes and Macrophages. Nat Rev Immunol 2020; 20: 355–362.
Riedel S, Morse SA, Mietzner TA, et al. Jawetz, Melnick & Adelberg's Medical Microbiology. 2019.
Rothan HA, Byrareddy SN. The Epidemiology and Pathogenesis of Coronavirus Disease (COVID-19) Outbreak. J Autoimmun 2020; 109: 102433.
Organization WH. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva, https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (2020).
Kam K-Q, Yung CF, Cui L, et al. A Well Infant with Coronavirus Disease 2019 with High Viral Load. Clin Infect Dis an Off Publ Infect Dis Soc Am 2020; 71: 847–849.
Cai H. Sex Difference and Smoking Predisposition in Patients with COVID-19. The Lancet. Respiratory Medicine 2020; 8: e20.
Fang L, Karakiulakis G, Roth M. Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection? The Lancet. Respiratory Medicine 2020; 8: e21.
Zhang C, Shi L, Wang F-S. Liver Injury in COVID-19: Management and Challenges. Lancet Gastroenterol Hepatol 2020; 5: 428–430.
Sharma R, Agarwal M, Gupta M, et al. Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19). Coronavirus Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and Therapeutics 2020; 55–70.
Gorbalenya AE, Baker SC, Baric RS, et al. The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCoV and Naming It SARS-CoV-2. Nat Microbiol 2020; 5: 536–544.
Zhou P, Yang X-L, Wang X-G, et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature 2020; 579: 270–273.
Susilo A, Rumende C, Pitoyo C, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. J Penyakit Dalam Indones 2020; 7: 45.
Chigr F, Merzouki M, Najimi M. Autonomic Brain Centers and Pathophysiology of COVID-19. ACS Chem Neurosci 2020; 11: 1520–1522.
Ng SC, Tilg H. COVID-19 and the Gastrointestinal Tract: More than Meets the Eye. Gut 2020; 69: 973–974.
Liu J, Liu Y, Xiang P, et al. Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage. medRxiv 2020; 2020.02.10.20021584.
Feng G, Zheng KI, Yan Q-Q, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol 2020; 8: 18–24.
Boettler T, Newsome PN, Mondelli MU, et al. Care of Patients with Liver Disease during the COVID-19 Pandemic: EASL-ESCMID Position Paper. JHEP Reports Innov Hepatol 2020; 2: 100113.
Wang L. C-Reactive Protein Levels in the Early Stage of COVID-19. Med Mal Infect 2020; 50: 332–334.
Zhang L, Li C, Zhou Y, et al. Persistent Viral Shedding Lasting Over 60 Days in a Mild COVID-19 Patient with Ongoing Positive SARS-CoV-2. Quant Imaging Med Surg 2020; 10: 1141–1144.
Carmo A, Pereira-Vaz J, Mota V, et al. Clearance and Persistence of SARS-CoV-2 RNA in Patients with COVID-19. J Med Virol 2020; 92: 2227–2231.
Yang J-R, Deng D-T, Wu N, et al. Persistent viral RNA Positivity during the Recovery Period of a Patient with SARS-CoV-2 Infection. J Med Virol. Epub ahead of print April 2020. DOI: 10.1002/jmv.25940.
Ravioli S, Ochsner H, Lindner G. Reactivation of COVID-19 pneumonia: A Report of Two Cases. The Journal of Infection 2020; 81: e72–e73.
Wong J, Koh WC, Momin RN, et al. Probable Causes and Risk Factors for Positive SARS-CoV-2 Test in Recovered Patients: Evidence from Brunei Darussalam. J Med Virol. Epub ahead of print June 2020. DOI: 10.1002/jmv.26199.
Wu R, Wang L, Kuo H-CD, et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Reports 2020; 1–15.
Ali N. Role of Vitamin D in Preventing of COVID-19 Infection, Progression and Severity. J Infect Public Health. Epub ahead of print 2020. DOI: https://doi.org/10.1016/j.jiph.2020.06.021.
Burhan E, Isbaniah F, Susanto AD. Pneumonia COVID-19: Diagnosis & Penatalaksanaan di Indonesia. Jakarta Perhimpun Dr Paru Indones.
Smith T, Bushek J, LeClaire A, et al. COVID-19 Drug Therapy. Elsevier.
Kumar A, Kubota Y, Chernov M, et al. Potential Role of Zinc Supplementation in Prophylaxis and Treatment of COVID-19. Med Hypotheses 2020; 144: 109848.
Anwar F, Altayb HN, Al-Abbasi FA, et al. Antiviral Effects of Probiotic Metabolites on COVID-19. J Biomol Struct Dyn 2020; 1–10.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (